News

The study demonstrated that single intravenous doses of 1 and 3mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2mcg for subsequent

Under the agreement, Glenmark is expected to manufacture the FDA approved products exclusively for Taro USA. Taro USA’s branded division, TaroPharma, a division that offers dermatologists and pediatricians

Under the terms of the agreement, Boehringer Ingelheim will pay Micromet an upfront cash payment of approximately $6.6m. Micromet will be eligible to receive development and regulatory milestone

AEZS-108 is doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in

LX1031 is an oral, serotonin synthesis inhibitor that acts locally in the gastrointestinal tract targeting tryptophan hydroxylase (TPH), an enzyme necessary for the production of serotonin. LX1031 is

Intellipharmaceutics, Par, Novartis Pharmaceuticals, Novartis Pharma, Celgene, Elan and Elan Pharma, have also entered into license agreements in conjunction with the settlements of the litigation concerning the company’s

Pharmacokinetic data from the initial Phase I trial of BNC210 reported on March 3, 2010 indicated that a plateau of absorption of BNC210 was observed at doses between

With this solution, pharmaceutical, biopharmaceutical and medical device / equipment companies can partner with their contract manufacturers (CMOs) and packagers (CPOs) to create a common view of production

Oramed Pharmaceuticals said that the randomised, double-blind, placebo-controlled, multi-centered study conducted in South Africa evaluated responses of 29 type 2 diabetes patients to ORMD-0801. Insulin-loaded or placebo capsules